Intravenous thrombolysis for ischaemic stroke is also safe and efficient without a specialised neuro-intensive care unit

Swiss Medical Weekly

Volumn 134, Issue 1-2, 2004, Pages 14-17

  Wiegand, Nico ^a   Lüthy, Regina ^a   Vogel, Barbara ^a   Straumann, Ediwin ^a   Beynon, Christopher ^a   Bertel, Osmund ^a   Oelz, Oswald ^a   Caspar, Clemens B ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Acute ischaemic stroke; Feasibility; Rt PA; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; PROUROKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTENSIVE CARE; MALE; PATIENT SELECTION; PROSPECTIVE STUDY; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; EMERGENCY HEALTH SERVICE; FEASIBILITY STUDY; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; TIME;

AGED; CEREBROVASCULAR ACCIDENT; EMERGENCY SERVICE, HOSPITAL; FEASIBILITY STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 1642536655     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke (ECASS I). JAMA 1995;274:1017-25.
3. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
4. Clark WM, Wissmann S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomised controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-26.
5. Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke 2002;33:493-6.
6. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischemic stroke (Cochrane Review). In: The Cochrane Library, Issue 4 1999. Oxford: Update Software.
7. Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999;53(7 Suppl 4): S3-14.
8. Bogousslavsky J, Buettner UW, Hess K, Le Floch-Rohr J, Lyrer Ph, Mattle H. Die Akutbehandlung des Schlaganfalls mittels intravenöser Thrombolyse mit rt-PA (recombinant tissue plasminogen activator). Schweiz Aerztezeitung 1998;79:112-3.
9. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association: Circulation 1996;94:1167-74.
10. Lyden P, Brott TG, Tilley B, Welch KMA, Mascha EJ, Levine S, et al. Improved reliability of the NIH stroke scale using video training. Stroke 1994;25:2220-6.
11. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA study. Neurology, 2000;55:1649-55.
12. Radovanovic D, personal communication (AMIS Plus Center, Zurich, Switzerland)
13. Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, Bratina PL, Yatsu FM, et al. Intravenous tissue plasminogen activator for ischemic stroke: Feasibility, safety and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
14. Grond M, Stenzel C, Schmülling S, Rudolf J, Neveling M, Lechleuthner A, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29:1544-9.
15. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience. JAMA 2000; 283:1151-8.
16. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 2000;283:1145-50.
17. Schmülling S, Grond M, Rudolf J, Heiss WD. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 2000;31:1552-4.
18. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campell M, Morgenstern LB, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-13.
19. Thomassen L, Waje-Andreassen U, Morsund HA, Hornes J, Maintz C, Smievoll AI, et al. Thrombolytic therapy in acute ischemic stroke. Cerebrovasc Dis 2002;13:163-7.
20. Albert MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, et al for the Brain Attack Coalition. Recommendations for the establishment of primary stroke centers. JAMA 2000;283: 3102-9.
21. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomised controlled trial. JAMA 1999;282:2003-11.
22. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000;343:710-22.
23. Engelter S, Lyrer P. Stroke units in der Schweiz: Bedarfsanalyse, Richtlinien und Anforderungsprofil. Swiss Medical Forum. (in press)p